Skip to main content
OUTCOME
8. Access to health technologies
Health Systems, Services and Life Course
8. Access to health technologies
Budget
Approved Budget PB (Previous)
38.0
US$ MILLION
Priority

Medium

Proposed Budget PB (Current)
41.5
US$ MILLION
Related Outputs and Indicators
  • 8.1.a. Number of countries and territories with updated national policies and/or strategies on access, quality, and use of medicines and other health technologies
    Baseline
    13
    Target
    19
  • 8.1.b. Number of countries and territories with policies and/or strategies on research and development, innovation, and/or manufacturing to promote access to affordable health products
    Baseline
    4
    Target
    6
  • 8.2.a. Number of countries and territories that have established an institutional development plan to improve regulatory capacity for health products based on the assessment of their national regulatory capacities by the Global Benchmarking Tool
    Baseline
    0
    Target
    28
  • 8.3.a. Number of countries and territories with a comprehensive strategy on multisource/generic medicines
    Baseline
    6
    Target
    7
  • 8.3.b. Number of countries and territories updating, developing, and implementing medicines pricing policies and monitoring systems
    Baseline
    6
    Target
    10
  • 8.4.a. Number of countries and territories implementing a national plan to strengthen access to radiological services and radiation safety
    Baseline
    8
    Target
    22
  • 8.4.b. Number of countries and territories implementing a national plan to strengthen access to pharmaceutical services
    Baseline
    3
    Target
    9
  • 8.4.c. Number of countries and territories implementing national strategies/mechanisms to improve access, quality, safety, or rational use of blood in their services
    Baseline
    10
    Target
    12
  • 8.4.d. Number of countries and territories implementing a national plan to strengthen access to transplant services
    Baseline
    9
    Target
    13
  • 8.5.a. Number of countries and territories implementing plans to manage and oversee the essential medicines supply chain, including planning, forecasting, and availability
    Baseline
    3
    Target
    11
  • 8.6.a. Number of countries and territories that have a strategy/mechanism for antibiotic sales estimation and that enforce antibiotic sales under prescription
    Baseline
    5
    Target
    7
  • 8.7.a. Number of countries and territories with mechanisms for health technology assessment and evidence-‌-based incorporation, selection, management, and rational use of medicines and other health technologies
    Baseline
    4
    Target
    10
How PASB will deliver

Key Technical Cooperation Interventions
 

  • Step up leadership
    • Promote and update policies, norms, and strategies that ensure timely access to and rational use of safe, affordable, quality-assured, and cost-effective health technologies, including but not limited to pharmaceuticals, vaccines and diagnostics, and medical devices.
    • Lead efforts in innovation through the Regional Platform to Advance the Manufacturing of COVID-19 Vaccines and other Health Technologies in the Americas. This includes increasing regional capacity for the research and development of priority health products; supporting the generation of ecosystems to enable development of, production of, and access to medicines and other health technologies; and guaranteeing genuinely equitable access to vaccines, medicines, and other health technologies during pandemics.
  • Support countries
    • Foster integrated health service delivery networks to strengthen and improve the organization of pharmaceutical, radiology, and blood and transplant services.
    • Provide guidance and training to countries in the strengthening of regulatory capacity for medicines and health technologies and in the application of international norms and standards to ensure the quality of medicines and other health technologies.
  • Produce technical products on norms and standards, data, and research
    • Strengthen the Revolving Fund for Access to Vaccines (Revolving Fund) and the Regional Revolving Fund for Strategic Public Health Supplies (Strategic Fund) with respect to access, effectiveness, and affordability assessment, and quality assessment and oversight of eligible products and suppliers.
    • Foster regional networks and other collaborative mechanisms to strengthen capacities, information sharing, and work sharing to improve governance and oversight of national health and regulatory authorities regarding the selection, incorporation, regulation, and use of medicines and other health technologies.